Romosozumab
Also known as: Evenity, AMG 785, CDP7851
Romosozumab is a monoclonal antibody that inhibits sclerostin, simultaneously stimulating bone formation while reducing bone resorption. This dual mechanism makes it a powerful therapeutic for treating severe osteoporosis in postmenopausal women.
Romosozumab is a 147.1 kDa research peptide. Romosozumab is a monoclonal antibody that inhibits sclerostin, simultaneously stimulating bone formation while reducing bone resorption. This dual mechanism makes it a powerful therapeutic for treating severe osteoporosis in postmenopausal women.
Also called: Evenity, AMG 785, CDP7851
147.1 kDa
Molecular Weight
Daltons
4
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
210-210
Typical Dose
mg
Overview
Romosozumab represents a breakthrough in osteoporosis treatment through its unique sclerostin inhibition mechanism. Unlike traditional bone therapies that either build bone or prevent bone loss, romosozumab does both simultaneously. The antibody binds to sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab unleashes osteoblast activity while dampening osteoclast function. This dual action creates an anabolic window where bone mineral density increases rapidly, particularly during the first year of treatment. Clinical trials demonstrate remarkable efficacy in reducing vertebral and hip fractures in high-risk patients. The treatment requires monthly subcutaneous injections and shows peak bone-building effects within 12 months, after which the anabolic response gradually diminishes. Research continues into optimal sequencing with other osteoporosis medications and potential applications in male osteoporosis.
Key Takeaways: Romosozumab
- Strongest evidence supports Romosozumab for rapid vertebral fracture reduction and significant hip fracture prevention
- Research doses typically range from 210 to 210 mg via subcutaneous
- 4 benefits with strong evidence, 3 moderate, 0 preliminary
- Half-life: 20-25 days
- 4 cited research studies in this guide
Mechanism of Action
Romosozumab binds to sclerostin with high affinity, preventing sclerostin from binding to LRP5 and LRP6 receptors on osteoblasts. This blockade removes the brake on Wnt signaling pathways, leading to increased osteoblast differentiation and bone formation. Simultaneously, romosozumab reduces RANKL expression, which decreases osteoclast activity and bone resorption. The net effect is a dramatic shift in bone remodeling balance toward formation, particularly pronounced in trabecular bone sites like the spine.
Research Benefits
Romosozumab at a Glance
Romosozumab binds to sclerostin with high affinity, preventing sclerostin from binding to LRP5 and LRP6 receptors on osteoblasts.
Rapid Vertebral Fracture Reduction
Strong EvidenceClinical trials show 73% reduction in new vertebral fractures within 12 months compared to placebo, with the most dramatic effects occurring in the first 6 months of treatment.
Significant Hip Fracture Prevention
Strong EvidenceReduces hip fracture risk by 38% compared to alendronate in head-to-head trials, with particular efficacy in patients with prior fracture history.
Exceptional Spine BMD Gains
Strong EvidenceIncreases lumbar spine bone mineral density by 13-17% within 12 months, the largest BMD increases seen with any osteoporosis medication.
Total Hip BMD Improvement
Strong EvidenceProduces 6-7% increases in total hip bone mineral density, with sustained improvements maintained during treatment duration.
Trabecular Microarchitecture Enhancement
Moderate EvidenceHigh-resolution CT studies demonstrate improved trabecular thickness, number, and connectivity, particularly in vertebral bodies where fracture risk is highest.
Cortical Bone Strengthening
Moderate EvidenceIncreases cortical thickness and reduces cortical porosity at key fracture sites, contributing to overall bone strength improvements.
Quality of Life Enhancement
Moderate EvidencePatients report reduced back pain, improved mobility, and better functional outcomes compared to traditional bisphosphonate therapy.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Severe postmenopausal osteoporosis | 210–210 mg | subcutaneous |
| Fracture prevention research | 140–280 mg | subcutaneous |
| Male osteoporosis investigation | 210–210 mg | subcutaneous |
Frequency
Once monthly
Timing
Any time of day, rotate injection sites
Cycle Length
12 months maximum recommended duration
Research Notes
- 1Treatment limited to 12 doses due to diminishing anabolic response
- 2Requires transition to antiresorptive therapy afterward
- 3Pre-dose calcium and vitamin D levels should be optimized
- 4Injection sites include thigh, abdomen, or upper arm
- 5Room temperature injection reduces discomfort
Reconstitution Guide
Standard Reconstitution
Vial Size
210 mg
Bacteriostatic Water
0 mL
Concentration
Infinity mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Romosozumab vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 0 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). Pre-filled pen stable for 30 days at room temperature.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
Pre-filled pen stable for 30 days at room temperature
Important Notes
- •Available as pre-filled pen or prefilled syringe
- •No reconstitution required - ready to inject
- •Allow to reach room temperature before injection
- •Protect from light during storage
- •Single-use device - discard after injection
Romosozumab Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Romosozumab Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Injection site reactions (pain, erythema, swelling)
- !Increased cardiovascular events (myocardial infarction, stroke)
- !Hypocalcemia, especially if vitamin D deficient
- !Joint pain and muscle pain
- !Headache and fatigue
- !Osteonecrosis of the jaw (rare but serious)
- !Atypical femoral fractures (very rare)
- !Hypersensitivity reactions including anaphylaxis
- !Upper respiratory tract infections
- !Cataract formation (observed in animal studies)
Potential Interactions
- ⚡Calcium supplements may affect absorption timing
- ⚡Vitamin D deficiency increases hypocalcemia risk
- ⚡Immunosuppressive drugs may increase infection risk
- ⚡Bisphosphonates should not be used concurrently
- ⚡Denosumab combination not recommended
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
FRAME trial demonstrated 73% reduction in vertebral fractures and 36% reduction in clinical fractures with romosozumab versus placebo in 7180 postmenopausal women.
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis
ARCH trial showed superior efficacy of romosozumab over alendronate, with 48% reduction in vertebral fractures and 19% reduction in hip fractures.
Effects of Romosozumab on Bone Mineral Density and Bone Turnover Markers
Phase 3 study demonstrated rapid increases in bone formation markers followed by decreases in resorption markers, with 11.3% lumbar spine BMD increase at 12 months.
Cardiovascular Safety of Romosozumab in Postmenopausal Women
Post-hoc analysis of cardiovascular events in FRAME and ARCH trials, identifying increased risk in patients with prior cardiovascular events.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Romosozumab is the only osteoporosis treatment that simultaneously increases bone formation and decreases bone breakdown. Traditional treatments either build bone (teriparatide) or prevent bone loss (bisphosphonates), but romosozumab does both through sclerostin inhibition.
The bone-building effects of romosozumab diminish over time as the body adapts to sclerostin blockade. After 12 months, bone formation markers return toward baseline while resorption markers remain suppressed, making continued treatment less effective than transitioning to antiresorptive therapy.
Clinical trials identified increased risks of heart attack and stroke, particularly in patients with existing cardiovascular disease. The FDA requires a black box warning about these risks, and romosozumab is contraindicated in patients who had a heart attack or stroke within the past year.
Romosozumab is currently approved only for postmenopausal women at high fracture risk. Studies in men are ongoing, but the medication has not yet received approval for male osteoporosis treatment.
After completing 12 months of romosozumab, patients typically transition to an antiresorptive medication like alendronate, risedronate, or denosumab to maintain the bone density gains achieved during romosozumab treatment.
Fracture reduction begins within the first few months of treatment. The most dramatic decreases in vertebral fracture risk occur within the first 6 months, with maximum bone density gains typically achieved by 12 months.
Common injection site reactions include pain, redness, and swelling that typically resolve within a few days. Rotating injection sites between the thigh, abdomen, and upper arm helps minimize reactions. Allowing the medication to reach room temperature before injection reduces discomfort.
Osteonecrosis of the jaw is a rare but serious side effect, occurring in less than 0.1% of patients. Risk increases with dental procedures, so patients should have a dental exam before starting treatment and maintain good oral hygiene throughout therapy.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.